Related Experiment Videos
[Current trends in coronary angioplasty]
1Departement Innere Medizin, Universitätsklinik Inselspital, Bern.
Insights
Coronary angioplasty and bypass surgery show similar outcomes, but angioplasty requires more reinterventions. Coronary stents and antiplatelet drugs improve outcomes, while other devices have limited clinical impact.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
Background:
- Coronary angioplasty is a rapidly evolving field.
- Balloon angioplasty and bypass surgery demonstrate comparable mid-term mortality and complication rates, as supported by BARI trial data.
- Balloon angioplasty is associated with a high reintervention rate and is not advised for diabetic patients with multivessel disease.
Purpose of the Study:
- To review the current status and advancements in coronary angioplasty.
- To evaluate the efficacy of coronary stents and adjunctive therapies.
- To discuss the clinical impact of novel interventional devices and techniques.
Main Methods:
- Review of clinical trial data and published literature on coronary angioplasty.
- Analysis of outcomes comparing balloon angioplasty, bypass surgery, and percutaneous transluminal coronary angioplasty (PTCA).
- Evaluation of the role of coronary stents, antiplatelet agents, and GP IIb/IIIa inhibitors.
Main Results:
- Balloon angioplasty and bypass surgery are equivalent for mortality and major complications in mid-term follow-up.
- Direct PTCA's superiority over thrombolytic therapy for acute myocardial infarction remains debated.
- Coronary stents have expanded their role, with antiplatelet agents (e.g., ticlopidine) reducing subacute stent thrombosis.
- GP IIb/IIIa inhibitors facilitate more aggressive interventional strategies for acute coronary syndromes.
Conclusions:
- Coronary angioplasty continues to advance, with stents and antiplatelet therapies significantly improving safety and efficacy.
- While effective, balloon angioplasty necessitates frequent reinterventions.
- Emerging technologies like laser angioplasty and local drug delivery have minimal current clinical impact.
Abstract:
Coronary angioplasty still is an area of intensive development. The publication of the BARI data confirms and consolidates previous findings that balloon angioplasty and bypass surgery are equivalent in terms of mortality and major complications over a mid-term follow-up period. However, balloon angioplasty has a high rate of reinterventions, and is not recommended in diabetic patients with multivessel disease. The question, whether direct PTCA is a better treatment strategy of acute myocardial infarction than thrombolytic therapy remains unsettled despite a slight advantage for direct PTCA in several small randomized trials. The role of coronary stents has continuously expanded over the last years, as a tool against acute as well as long-term complications of angioplasty. This success is partly due to the finding that antiplatelet agents such as ticlopidine offer an effective protection against subacute stent thrombosis. The introduction of the GP IIb/IIIa platelet receptor blockers has provided another powerful tool against acute thrombotic complications, leading to a more aggressive interventional strategy in acute coronary syndromes. The development of alternative "devices" has further slowed down because of repeated publication of negative clinical results. Although different forms of laser energy applications, of local drug delivery, and of local irradiation are interesting research areas, their current impact on clinical practice is small.